Lung Cancer
25 videos · last 6 months shuffled daily, then older videos newest first
▶
2:43 Current and Emerging HER2-targeted Therapies in NSCLC
Nicolas Girard, MD, PhD, of Institut Curie on HER2-targeted therapies in non-small cell lung cancer, including the ongoing DESTINY-Lung04 study of trastuzumab deruxtecan and data on zongertinib and sevabertinib.
▶
9:38 SHERLOCK Trial: Sotorasib in KRAS G12C Lung Cancer
A/Prof Surein Arulananda summarises the findings of the SHERLOCK trial of first-line sotorasib in non-squamous non-small cell lung cancer with the KRAS G12C mutation, for TOGA.
▶
1:46 Local Consolidative Therapy with Osimertinib: NorthStar Trial Background and Secondary Analysis
Saumil Ghandi, MD, PhD, of MD Anderson on the rationale and secondary analysis of the NorthStar trial, which added radiation or surgery alongside continued osimertinib.
▶
2:19 Updated Results from PALOMA-2: First-Line Subcutaneous Amivantamab Plus Lazertinib in NSCLC
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses updated results from the PALOMA-2 trial (NCT05498428) of first-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced non-small cell lung cancer (NSCLC).
▶
4:06 BBC North West News Report of the NEOVACC Clinical Trial at The Clatterbridge Cancer Centre
BBC North West News Health Correspondent Gill Dummigan reports on the NEOVACC clinical trial at Clatterbridge Cancer Centre - Liverpool. She interviews patient Chris Jones, the first person in the world to have this particular cancer vaccine for the most common lung cancer.
▶
16:56 Small Cell Lung Cancer Research: Dr. Ashish Saxena
Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, discusses small cell lung cancer trials for Lung Cancer Foundation of America, covering patient-reported outcomes and immunotherapy and antibody drug conjugate research.
▶
1:47 Calderasib, a Novel KRAS G12C-off Inhibitor in NSCLC: Insights from the KANDLELIT-001 Trial
Adrian Sacher, MD, of Princess Margaret Cancer Centre presents KANDLELIT-001 data on calderasib, a KRAS G12C-off inhibitor, alone and with pembrolizumab or chemotherapy in G12C-mutated lung cancer.
▶
18:54 OTEOB From ASCO 2026: What’s Changing in Prostate, Lung and Multiple Myeloma Research
Monty Pal, M.D., talks with Alan Bryce, M.D., Kristin Higgins, M.D., and Joseph Mikhael, M.D., of City of Hope about the prostate, lung and multiple myeloma research shaping conversations at ASCO 2026.
▶
2:55 IMMUNO-BIOMAP: Predicting Immunotherapy Response in NSCLC
Ravi Salgia, MD, PhD, of City of Hope explains the biomarker-driven design of IMMUNO-BIOMAP, an ARPA-H-funded phase 2 trial aiming to enrol 535 patients with metastatic NSCLC to predict who benefits from first-line immunotherapy, for Targeted Oncology.
▶
25:44 Precision Oncology in Lung Cancer with Boehringer Ingelheim’s Itziar Canamasas & Volker Teichgräber
Vera Kovacevic talks to Itziar Canamasas, PhD, Global Head of Oncology, and Volker Teichgräber, MD, Head of Global Experimental Medicine Oncology, both of Boehringer Ingelheim, about precision oncology in lung cancer.
▶
2:02 DeLLphi-312: Tarlatamab with Chemoimmunotherapy for First-Line Treatment of ES-SCLC
Second-line tarlatamab improved overall and progression-free survival in a Phase Ib trial in extensive-stage small-cell lung cancer, leading to the Phase III DeLLphi-312 study in the first line.
▶
1:22:15 GO2 Living Room July 21st, 2026 - Lung Cancer News and Highlights from ASCO 2026
GO2 for Lung Cancer on lung cancer news and highlights from ASCO 2026.
▶
39:29 ASCO 2026: Highlights and Analysis
Associate Professor Bishal Gyawali talks to ecancer about ASCO 2026 presentations across GI, pancreatic, lung, breast and prostate cancer, including daraxonrasib in metastatic pancreatic adenocarcinoma.
▶
16:53 Zoldenrasib in KRAS G12D-Mutant NSCLC: Phase 1 Data
OncologyTube presents RMC-9805-001 Phase 1 data from AACR 2026 on zoldenrasib, a KRAS G12D ON-state inhibitor, in previously treated KRAS G12D-mutant non-small cell lung cancer, covering study design, safety, response rates, PFS and ctDNA response.
▶
1:13:51 Best of ASCO 2026: Lung Cancer Research
Kyle Concannon, MD, of the University of Colorado Cancer Center reviews lung cancer research presented at ASCO 2026 for GO2 for Lung Cancer, including long-term CROWN follow-up of lorlatinib and the LIBRETTO-432 trial of selpercatinib.
▶
1:10 Beamion LUNG-1: Zongertinib in Treatment-Naïve HER2-mutant NSCLC and in Those with Brain Metastases
Adrian Sacher, MD, MMSc, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, comments on findings from the Beamion LUNG-1 study (NCT04886804) examining zongertinib in treatment-naïve HER2-mutant non-small cell lung cancer (NSCLC) and in patients with brain metastases.
▶
1:16 TAISHAN-302: B7-H3 ADC in Small Cell Lung Cancer
WeTrials summarises the Phase 3 TAISHAN-302 trial, in which 451 patients with relapsed small cell lung cancer received the B7-H3 antibody-drug conjugate tambotatug pelitecan or topotecan, with interim median overall survival of 13.3 versus 9.4 months.
▶
3:14 ASPiRATION Genomic Profiling Study in Lung Cancer
TOGA updates the ASPiRATION study of comprehensive genomic profiling in metastatic NSCLC and its Phase II single-arm substudies, run with Omico and the NHMRC Clinical Trials Centre at the University of Sydney.
▶
58:46 [LTRN Webinar] Inside the Data - LP-184 Phase 1a Results and Future Trials with Dr. Igor Astsaturov
Lantern Pharma and Dr. Igor Astsaturov of Fox Chase Cancer Center review Phase 1a results for LP-184, a synthetic lethal candidate for advanced solid tumours, and plans for further trials.
▶
3:14 Black Diamond Therapeutics BDTX-1535
Matthew Lucas, PhD, Black Diamond Therapeutics, Cambridge, MA, talks on BDTX-1535, an inhibitor of selected EGFR mutations in non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).
▶
6:15 Native American and Indigenous Participation in Clinical Trials
Lung cancer is a leading cause of death from cancer among Native Americans, and this video looks at the importance of Native American representation in clinical trials along with disparities affecting Native Americans with lung cancer.
▶
4:01 ALK-Positive NSCLC: Ensartinib and Crizotinib Data
A Cancer Nursing Today roundtable led by Stephen Liu, MD, of Georgetown Lombardi, with Shirish Gadgeel, MD, and others, discusses ensartinib in ALK-positive NSCLC and crizotinib data presented at the 2025 IASLC World Conference on Lung Cancer.
▶
5:44 Why Lung MAP Matters for MET Lung Cancer Patients
Marcia Horn of the International Cancer Advocacy Network on why Lung MAP matters for MET-driven lung cancer: three arms, each matching a patient's biomarker to a targeted therapy.
▶
10:34 Early-Stage ALK-Positive Lung Cancer and the ALINA Trial
A Cancer Nursing Today roundtable moderated by Stephen Liu, MD, of Georgetown Lombardi discusses disease-free survival in the ALINA trial, which randomised resected ALK-positive NSCLC to alectinib or chemotherapy, and how chemotherapy's role has changed.